Published in Br J Cancer on September 28, 2001
Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg (2005) 4.13
Survival analysis part I: basic concepts and first analyses. Br J Cancer (2003) 4.08
Survival analysis part II: multivariate data analysis--an introduction to concepts and methods. Br J Cancer (2003) 3.06
Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J (2010) 2.57
Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol (2009) 2.12
Comparison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study. BMC Med Res Methodol (2010) 2.05
Survival analysis part IV: further concepts and methods in survival analysis. Br J Cancer (2003) 1.77
Comparison of imputation methods for handling missing covariate data when fitting a Cox proportional hazards model: a resampling study. BMC Med Res Methodol (2010) 1.26
Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation. Br J Cancer (2003) 1.23
The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int J Clin Exp Pathol (2011) 1.06
Methylation of tumor suppressor genes in ovarian cancer. Exp Ther Med (2012) 1.00
A molecularly targeted theranostic probe for ovarian cancer. Mol Cancer Ther (2010) 0.98
Mediation analysis of the relationship between institutional research activity and patient survival. BMC Med Res Methodol (2014) 0.96
Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer (2004) 0.94
External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer. Br J Cancer (2013) 0.89
Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. Eur Radiol (2007) 0.88
Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. Br J Cancer (2012) 0.88
Choice of approach for hepatectomy for hepatocellular carcinoma located in the caudate lobe: isolated or combined lobectomy? World J Gastroenterol (2012) 0.87
Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. Gynecol Oncol (2015) 0.86
Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival. Oncotarget (2016) 0.86
The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Arch Gynecol Obstet (2010) 0.83
Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics. J Ovarian Res (2015) 0.79
Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012. J Gynecol Oncol (2015) 0.79
Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer. Gynecol Oncol (2015) 0.78
Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer. Int J Gynecol Cancer (2015) 0.78
Prognostic Impact of ABO Blood Group on the Survival in Patients with Ovarian Cancer. J Cancer (2015) 0.78
Hypertabastic survival model. Theor Biol Med Model (2007) 0.77
Developing a multivariable prognostic model for pancreatic endocrine tumors using the clinical data warehouse resources of a single institution. Appl Clin Inform (2010) 0.77
Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma. Int Sch Res Notices (2014) 0.77
Modeling prognostic factors in resectable pancreatic adenocarcinomas. Cancer Inform (2010) 0.76
The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer. Int J Gynecol Cancer (2015) 0.76
Role of PAR-4 in ovarian cancer. Oncotarget (2015) 0.76
Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer. Anal Cell Pathol (Amst) (2016) 0.75
DEF6 expression in ovarian carcinoma correlates with poor patient survival. Diagn Pathol (2016) 0.75
Outcome of vulvar reconstruction in patients with advanced and recurrent vulvar malignancies. BMC Cancer (2015) 0.75
Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis. Sci Rep (2015) 0.75
Impact of Clinical Pharmacy Services on KAP and QOL in Cancer Patients: A Single-Center Experience. Biomed Res Int (2015) 0.75
Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB. Oncol Lett (2015) 0.75
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. Oncologist (2017) 0.75
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med (1996) 46.18
Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med (1999) 18.50
A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol (1995) 9.27
What do we mean by validating a prognostic model? Stat Med (2000) 9.18
FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol (1994) 2.10
Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol (2000) 1.87
Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol (1991) 1.77
The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer (1994) 1.37
The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol (1995) 1.34
Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol (1999) 1.33
Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol (1985) 1.28
Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol (1993) 1.25
Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol (1995) 1.17
Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol (1994) 1.10
Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma. Cancer Res (1990) 1.07
Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol (1989) 1.04
Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). Br J Cancer (1990) 1.03
Clinico-pathological correlates in ovarian cancer. Bull Cancer (1982) 1.00
Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma. J Clin Pathol (1996) 0.99
Advanced ovarian cancer. Neural network analysis to predict treatment outcome. Ann Oncol (1993) 0.96
Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. Br J Cancer (1995) 0.94
Survival determinants in patients with advanced ovarian cancer. Gynecol Oncol (1993) 0.93
EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. J Obstet Gynaecol (Tokyo 1995) (1995) 0.93
A practical device for the application of a diagnostic or prognostic function. Methods Inf Med (1978) 0.92
Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: a 15-year review. Int J Gynecol Cancer (1993) 0.91
CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer (1999) 0.88
Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance. Anticancer Res (1997) 0.84
Statistical methods for assessing agreement between two methods of clinical measurement. Lancet (1986) 211.50
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA (1995) 45.41
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet (2001) 31.74
Measuring agreement in method comparison studies. Stat Methods Med Res (1999) 31.11
Multiple significance tests: the Bonferroni method. BMJ (1995) 23.46
Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ (2001) 20.65
Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) (1986) 18.51
Analysis of serial measurements in medical research. BMJ (1990) 16.69
Cronbach's alpha. BMJ (1997) 13.79
The scandal of poor medical research. BMJ (1994) 11.58
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med (2001) 11.48
Statistical guidelines for contributors to medical journals. Br Med J (Clin Res Ed) (1983) 10.90
Statistics notes. Logarithms. BMJ (1996) 10.56
Statistics in medical journals. Stat Med (1983) 9.80
Evaluating non-randomised intervention studies. Health Technol Assess (2003) 9.69
Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet (1995) 9.14
Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ (2001) 8.98
Statistics and ethics in medical research: III How large a sample? Br Med J (1980) 8.78
Better reporting of randomised controlled trials: the CONSORT statement. BMJ (1996) 8.39
More informative abstracts revisited. Ann Intern Med (1990) 8.26
Transforming data. BMJ (1996) 6.78
Regression towards the mean. BMJ (1994) 6.57
Measurement error. BMJ (1996) 6.18
Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA (1994) 5.80
Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion (1999) 5.67
Statistics notes. The odds ratio. BMJ (2000) 5.61
The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol (2001) 5.43
Applying the right statistics: analyses of measurement studies. Ultrasound Obstet Gynecol (2003) 5.40
How can medical journals help prevent poor medical research? Some opportunities presented by electronic publishing. Lancet (1999) 5.27
Statistics notes. Interaction 2: Compare effect sizes not P values. BMJ (1996) 5.18
Correlation, regression, and repeated data. BMJ (1994) 4.88
Calculating correlation coefficients with repeated observations: Part 1--Correlation within subjects. BMJ (1995) 4.87
REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85
Social factors and height of primary schoolchildren in England and Scotland. J Epidemiol Community Health (1978) 4.73
Randomisation. BMJ (1991) 4.66
Patients' preferences and randomised trials. Lancet (1996) 4.64
Measurement error and correlation coefficients. BMJ (1996) 4.38
Indirect comparisons of competing interventions. Health Technol Assess (2005) 4.33
Statistical aspects of prognostic factor studies in oncology. Br J Cancer (1994) 4.22
Measurement error. BMJ (1996) 4.13
Survival analysis part I: basic concepts and first analyses. Br J Cancer (2003) 4.08
Some examples of regression towards the mean. BMJ (1994) 4.01
Survival probabilities (the Kaplan-Meier method). BMJ (1998) 3.98
Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol (2007) 3.84
A catalogue of reporting guidelines for health research. Eur J Clin Invest (2010) 3.83
Effects of a drug overdose in a television drama on presentations to hospital for self poisoning: time series and questionnaire study. BMJ (1999) 3.52
Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists. BMJ (2011) 3.50
The benefits and harms of breast cancer screening: an independent review. Br J Cancer (2013) 3.43
Transformations, means, and confidence intervals. BMJ (1996) 3.42
Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ (1995) 3.35
Measurement error proportional to the mean. BMJ (1996) 3.34
National study of health and growth: standards of attained height, weight and triceps skinfold in English children 5 to 11 years old. Ann Hum Biol (1977) 3.23
The use of transformation when comparing two means. BMJ (1996) 3.22
A note on the use of the intraclass correlation coefficient in the evaluation of agreement between two methods of measurement. Comput Biol Med (1990) 3.18
Interaction 3: How to examine heterogeneity. BMJ (1996) 3.17
Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer (2004) 3.15
Survival analysis part II: multivariate data analysis--an introduction to concepts and methods. Br J Cancer (2003) 3.06
Calculating correlation coefficients with repeated observations: Part 2--Correlation between subjects. BMJ (1995) 2.94
Randomised trial of educational visits to enhance use of systematic reviews in 25 obstetric units. BMJ (1998) 2.94
Outcome selection bias in meta-analysis. Stat Methods Med Res (2005) 2.86
Statistics and ethics in medical research. VI--Presentation of results. Br Med J (1980) 2.85
WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79
The effects of combining education and enforcement to reduce tobacco sales to minors. A study of four northern California communities. JAMA (1991) 2.77
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. J Am Podiatr Med Assoc (2001) 2.71
Survival analysis Part III: multivariate data analysis -- choosing a model and assessing its adequacy and fit. Br J Cancer (2003) 2.71
Baseline comparisons in randomized clinical trials. Stat Med (1991) 2.69
Predictors of physician's smoking cessation advice. JAMA (1991) 2.66
More informative abstracts. Ann Intern Med (1987) 2.63
Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet (2001) 2.61
One and two sided tests of significance. BMJ (1994) 2.61
Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res (1988) 2.40
Monitoring of large randomised clinical trials: a new approach with Bayesian methods. Lancet (2001) 2.35
Malignant melanoma in Scotland 1979-1983. Lancet (1985) 2.30
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
The efficacy of problem-solving treatments after deliberate self-harm: meta-analysis of randomized controlled trials with respect to depression, hopelessness and improvement in problems. Psychol Med (2001) 2.22
Statistics notes: blinding in clinical trials and other studies. BMJ (2000) 2.17
Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials (2000) 2.04
Serum immunoglobulin concentrations in preschool children measured by laser nephelometry: reference ranges for IgG, IgA, IgM. J Clin Pathol (1983) 2.04
Association between gas cooking and respiratory disease in children. Br Med J (1977) 2.03
Statistics and ethics in medical research. Misuse of statistics is unethical. Br Med J (1980) 2.02
An outline of the revised British Hypertension Society protocol for the evaluation of blood pressure measuring devices. J Hypertens (1993) 1.99
Issues in data monitoring and interim analysis of trials. Health Technol Assess (2005) 1.96
The relation between treatment benefit and underlying risk in meta-analysis. BMJ (1996) 1.96
Authors should make their data available. BMJ (2001) 1.92
Is the statistical assessment of papers submitted to the "British Medical Journal" effective? Br Med J (Clin Res Ed) (1983) 1.92
The cost-effectiveness of three smoking cessation programs. Am J Public Health (1987) 1.91
Comparing two methods of clinical measurement: a personal history. Int J Epidemiol (1995) 1.87
Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology (1985) 1.86
Statisticians in medical schools. J R Coll Physicians Lond (1990) 1.81
Estimating with confidence. Br Med J (Clin Res Ed) (1988) 1.79
Health effects due to occupational exposure to cobalt blue dye among plate painters in a porcelain factory in Denmark. Scand J Work Environ Health (1988) 1.78
Survival analysis part IV: further concepts and methods in survival analysis. Br J Cancer (2003) 1.77
A survey of the nutritional status of schoolchildren. Relation between nutrient intake and socio-economic factors. Br J Prev Soc Med (1973) 1.76
Sustainable rates of sebum secretion in acne patients and matched normal control subjects. J Am Acad Dermatol (1983) 1.72
A note on the calculation of expected survival, illustrated by the survival of liver transplant patients. Stat Med (1991) 1.72
Odds ratios should be avoided when events are common. BMJ (1998) 1.71
[CONSORT statement. Revised findings on quality improvement based on reports from randomized studies in parallel design]. Schmerz (2005) 1.70